NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
Clinical Trials
9 trialsNCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02728388 2025-05-08
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Medical College of Wisconsin
Phase 2 Recruiting
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02988726 2017-07-26
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Burzynski Research Institute
Phase 2 Terminated